Interní Med. 2013; 15(3-4): 114-117
New trends in pharmacotherapy of type 2 diabetes
- Diabetologické centrum IK, Krajská nemocnice T. Bati, a. s.
Recommended steps for treatment of hyperglycemia during the type 2 diabetes are orientated towards patients. Medical treatment
should minimalize undesirable effects of therapy and decrease the danger of rising of vascular complications. The most serious danger
consequent upon diabetes therapy is commencement of hypoglycemia accidents. One of the obstacles of effective therapy of diabetes
is caused by worries of hypoglycemia accident. Diabetes mellitus is developing disease, which needs active change of treatment, which
depend on progress to achieve individual aims of control. The lowest possibility of hyporglycemia accidents contained therapy by metformin,
DPP-4 inhibitors, GLP-1 agonists and insulin analogues. Glifloziny recently participate in therapy of diabetes and also glitazary,
which activate PPAR receptors, seem perspective. Individual therapy requires close cooperation with patient to achieve mutual agreement
regarding method of medical treatment.
Keywords: type 2 diabetes mellitus, hypoglycemia, antidiabetic agents, individual therapy
Published: March 20, 2013 Show citation
References
- Wright A, Burden AC, Paisey RB, et al. Sulfynlurea inadequacy: efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the U.K. Prospective Diabetes Study (UKPDS 57). Diabetes Care 2002; 25: 330-336.
Go to original source... 
Go to PubMed... - Peyrot M, Barnett AH, Meneghini LF, et al. Insulin adherence behaviours and barriers in the multinational Global Attitudes of Patients and Physicians in Insulin Therapy study. Diabet Med 2012; 29: 682-689. Go to original source... Go to PubMed...
- UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet, 1998; 352: 837-835. Go to original source...
- Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association fot the Study of Diabetes (EASD). Diabetes Care Publish Ahead of Print online April 19, 2012.
- Gantz I, Chen M, Mirza A, et al. Effect of MK-3102, a novel once-weekly DPP-4 inhibitor, over 12 weeks in patients with type 2 diabetes mellitus. Diabetologia 2012; 55(Suppl) S51.
- Rizzo MR, Barbieri M, Marfella R, et al. Reduction of oxidative stress and inflammation by bluting daily acute glucose fluctuations in patients with type 2 diabetes: role of dipeptidylpeptidase-IV inhibition. Diabetes Care 2012; 35(10): 2076-2082. Go to original source... Go to PubMed...
- Gallwitz B, Rosenstock J, Rauch T, et al. 2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial. Lancet 2012; Aug 4; 380: 475-483. Go to original source... Go to PubMed...
- Noyan-Ashraf MH, Momen MA, Ban K, et al. GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice. Diabetes 2009; 58: 975-983. Go to original source... Go to PubMed...
- Becker R, Ruus P, Liu Y, Kapitza C, Restoration of insulin release with lixisenatide in patients with type 2 diabetes [abstract], Diabetologia 2010; 53(Suppl. 1): S339.
- Bolli G, et al. Efficacy and Safety of Lixisenatide Once-Daily Versus Placebo in Patients with Type 2 Diabetes Insufficiently Controlled on Metformin (GetGoal-F1). Diabetes 2011; 60 (Suppl 1A) Poster 784.
- Blevins T, Pullman J, Malloy J, et al. Duration-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patinets with type 2 diabetes. J Clin End Met 2011; 96(5): 1301-1310. Go to original source... Go to PubMed...
- Henry RR, Lincoff AM, Mudaliar S, et al. Effect of the dual peroxisome proliferator-activated receptor-alpha/gamma agonist aleglitazar on risk of cardiovascular disease in patients with type 2 diabetes (SYNCHRONY): a phase II, randomised, dose-ranging study. Lancet 2009; 374(9684): 126-135. Go to original source... Go to PubMed...
- Fonseca V, Gill J, Zhou R, et al. An analysis of early insulin glargine added to metformin with or without sulfonylurea: impact on glycaemic control and hypoglycaemia. Diabetes, Obesity and Metabolism 2011; 13(9): 814-822. Go to original source... Go to PubMed...
- The ORIGIN trial investigators. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med 2012; 367(4): 319-328. Go to original source... Go to PubMed...
- Bergenstal RM, Rosenstock J, Arakaki RF, et al. Weight loss and lower nocturnal hypoglycaemia with nove long-acting basal insulin LY2605541 versus insulin glargine in patients type 2 diabetes. Diabetologia 2012; 55(Suppl): S377.
- Klonoff DC, Bergenstal RM, Bailey T, et al. Human hyaluronidase+rapid analogue insulin (RAI) improves postprandial glycaemic control in type 2 diabetes compared to insulin lispro alone. Diabetologia 2012; 55(Suppl): S372.